Osteoglycin Antibody (E-9): sc-365228

Osteoglycin Antibody (E-9) is a mouse monoclonal IgG1 antibody that detects Osteoglycin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Osteoglycin, also known as osteoinductive factor (OIF), plays a crucial role in bone formation by interacting with transforming growth factor beta (TGFβ) isoforms, specifically TGFβ1 and TGFβ2, to promote osteogenesis. This secreted protein is primarily found in bone tissues, where Osteoglycin contributes to the organization of the extracellular matrix and regulates cellular activities related to bone development and remodeling. The precursor form of Osteoglycin, referred to as Mimecan, undergoes proteolytic cleavage to yield the mature protein, highlighting the importance of post-translational modifications in functional activation. By facilitating the binding of TGFβ, Osteoglycin not only influences bone formation but also plays a significant role in various physiological processes, making Osteoglycin a vital target for research in bone biology and related disorders. Anti-Osteoglycin antibody (E-9) is an essential tool for scientists studying the intricate mechanisms of bone development and the extracellular matrix.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Osteoglycin Antibody (E-9) References:

1. Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening.  |  Van Aelst, LN., et al. 2015. Circ Res. 116: 425-36. PMID: 25520363
2. Osteoglycin's embracement of VEGF receptor-2 limits angiogenesis and collateralization.  |  van Hinsbergh, VW. 2017. Cardiovasc Res. 113: 10-12. PMID: 28069698
3. Low Levels of Plasma Osteoglycin in Patients with Complex Coronary Lesions.  |  Seki, T., et al. 2018. J Atheroscler Thromb. 25: 1149-1155. PMID: 29503411
4. Osteoglycin, a novel coordinator of bone and glucose homeostasis.  |  Lee, NJ., et al. 2018. Mol Metab. 13: 30-44. PMID: 29799418
5. Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes.  |  Starup-Linde, JK., et al. 2021. Front Endocrinol (Lausanne). 12: 649718. PMID: 33790870
6. Osteoglycin Across the Adult Lifespan.  |  Woessner, MN., et al. 2022. J Clin Endocrinol Metab. 107: e1426-e1433. PMID: 34850904
7. Elevated plasma levels of osteoglycin in cardiovascular patients: a systematic review and meta-analysis.  |  Zuo, Z., et al. 2022. Ann Palliat Med. 11: 498-505. PMID: 35249327
8. Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events.  |  Al-Sharify, D., et al. 2022. Atherosclerosis. 355: 8-14. PMID: 35850021
9. Osteoglycin: An ECM Factor Regulating Fibrosis and Tumorigenesis.  |  Nulali, J., et al. 2022. Biomolecules. 12: PMID: 36421687
10. Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology.  |  González-Salvatierra, S., et al. 2023. Am J Physiol Endocrinol Metab. 325: E649-E660. PMID: 37819194

The preferred Osteoglycin antibody is Osteoglycin Antibody (G-1): sc-374463.